These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 1377119

  • 1. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.
    Fitton A, Faulds D, Goa KL.
    Drugs; 1992 Apr; 43(4):561-96. PubMed ID: 1377119
    [Abstract] [Full Text] [Related]

  • 2. Moclobemide. An update of its pharmacological properties and therapeutic use.
    Fulton B, Benfield P.
    Drugs; 1996 Sep; 52(3):450-74. PubMed ID: 8875133
    [Abstract] [Full Text] [Related]

  • 3. Moclobemide: therapeutic use and clinical studies.
    Bonnet U.
    CNS Drug Rev; 2003 Sep; 9(1):97-140. PubMed ID: 12595913
    [Abstract] [Full Text] [Related]

  • 4. A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
    Norman TR, Burrows GD.
    Drug Saf; 1995 Jan; 12(1):46-54. PubMed ID: 7741983
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of reversible monoamine oxidase inhibitors in depressive illness.
    Roth M, Guelfi JD.
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():18-24. PubMed ID: 1394027
    [Abstract] [Full Text] [Related]

  • 6. Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states.
    Stabl M, Biziére K, Schmid-Burgk W, Amrein R.
    J Neural Transm Suppl; 1989 Sep; 28():77-89. PubMed ID: 2677244
    [Abstract] [Full Text] [Related]

  • 7. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
    Dingemanse J, Kneer J, Fotteler B, Groen H, Peeters PA, Jonkman JH.
    J Clin Psychopharmacol; 1995 Feb; 15(1):41-8. PubMed ID: 7714227
    [Abstract] [Full Text] [Related]

  • 8. RIMA: a safe concept in the treatment of depression with moclobemide.
    Amrein R, Hetzel W, Stabl M, Schmid-Burgk W.
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030
    [Abstract] [Full Text] [Related]

  • 9. Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation.
    Jouvent R, Le Houezec J, Payan C, Mikkelsen H, Fermanian J, Millet V, Dufour H.
    Psychiatry Res; 1998 Jul 13; 79(3):267-75. PubMed ID: 9704873
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M, Keller HH, Kettler R.
    Psychiatr Prax; 1989 Aug 13; 16 Suppl 1():18-24. PubMed ID: 2587673
    [Abstract] [Full Text] [Related]

  • 11. RIMA--a new concept in the treatment of depression with moclobemide.
    Amrein R, Hetzel W, Stabl M, Schmid-Burgk W.
    Int Clin Psychopharmacol; 1993 Jan 13; 7(3-4):123-32. PubMed ID: 8468432
    [Abstract] [Full Text] [Related]

  • 12. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.
    Versiani M, Nardi AE, Figueira IL, Stabl M.
    Acta Psychiatr Scand Suppl; 1990 Jan 13; 360():24-8. PubMed ID: 2123366
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies.
    Delini-Stula A, Mikkelsen H, Angst J.
    J Affect Disord; 1995 Oct 09; 35(1-2):21-30. PubMed ID: 8557884
    [Abstract] [Full Text] [Related]

  • 14. Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients.
    Nair NP, Ahmed SK, Kin NM, West TE.
    Acta Psychiatr Scand Suppl; 1995 Oct 09; 386():28-35. PubMed ID: 7717092
    [Abstract] [Full Text] [Related]

  • 15. [Moclobemide in the treatment of depression--an overview].
    Laux G.
    Psychiatr Prax; 1989 Aug 09; 16 Suppl 1():37-40. PubMed ID: 2685855
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Burkard WP, Bonetti EP, Da Prada M, Martin JR, Polc P, Schaffner R, Scherschlicht R, Hefti F, Müller RK, Wyss PC.
    J Pharmacol Exp Ther; 1989 Jan 09; 248(1):391-9. PubMed ID: 2913284
    [Abstract] [Full Text] [Related]

  • 17. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders.
    Priest RG, Gimbrett R, Roberts M, Steinert J.
    Acta Psychiatr Scand Suppl; 1995 Jan 09; 386():40-3. PubMed ID: 7717094
    [Abstract] [Full Text] [Related]

  • 18. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
    Lavian G, Finberg JP, Youdim MB.
    Clin Neuropharmacol; 1993 Jan 09; 16 Suppl 2():S1-7. PubMed ID: 8313392
    [Abstract] [Full Text] [Related]

  • 19. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.
    Wilde MI, Plosker GL, Benfield P.
    Drugs; 1993 Nov 09; 46(5):895-924. PubMed ID: 7507038
    [Abstract] [Full Text] [Related]

  • 20. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
    Da Prada M, Kettler R, Keller HH, Burkard WP, Haefely WE.
    J Neural Transm Suppl; 1989 Nov 09; 28():5-20. PubMed ID: 2677242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.